Stock analysis, AI verdict, fundamentals & technical signals
Rating: HOLD
Price: $100.80 Analyst target: $106.99 Upside: 6.14%
Lantheus Holdings, Inc. develops, manufactures and markets diagnostic and therapeutic agents and products that assist physicians in the diagnosis and treatment of heart, cancer and other diseases worldwide. The company is headquartered in North Billerica, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.